We have 3 of 725 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
CP volume was increased in both active RMS and inactive PMS and was associated with lower total and cortical brain volumes, suggesting CP volume may reflect processes beyond MS-specific pathology, including physiological factors.
DN-NMOSD is a heterogenous, severe and highly relapsing disease, where attacks lead to irreversible dysfunction, and the administration of maintenance immunotherapy reduces the relapse risk and should be considered early to prevent further disability.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
